Literature DB >> 9334404

Activation of ErbB2 during wallerian degeneration of sciatic nerve.

Y K Kwon1, A Bhattacharyya, J A Alberta, W V Giannobile, K Cheon, C D Stiles, S L Pomeroy.   

Abstract

We used anti-phosphopeptide-immunodetecting antibodies as immunohistochemical reagents to define the location and activity state of p185(erbB2) during Wallerian degeneration. Nerve damage induces a phosphorylation event at Y1248, a site that couples p185(erbB2) to the Ras-Raf-MAP kinase signal transduction pathway. Phosphorylation of p185(erbB2) occurs within Schwann cells and coincides in time and space with Schwann cell mitotic activity, as measured by bromodeoxyuridine uptake. These visual images of receptor autophosphorylation link activation of p185(erbB2) to the Schwann cell proliferation that accompanies nerve regeneration.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9334404      PMCID： PMC6573732     

Source DB:  PubMed          Journal:  J Neurosci        ISSN： 0270-6474            Impact factor:   6.167


  35 in total

1.  Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product.

Authors:  Y Mikami; J G Davis; K Dobashi; W C Dougall; J N Myers; V I Brown; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

2.  Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor.

Authors:  R J Epstein; B J Druker; T M Roberts; C D Stiles
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

Review 3.  Peripheral nerve regeneration.

Authors:  J W Fawcett; R J Keynes
Journal:  Annu Rev Neurosci       Date:  1990       Impact factor: 12.449

Review 4.  The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies.

Authors:  W C Dougall; X Qian; N C Peterson; M J Miller; A Samanta; M I Greene
Journal:  Oncogene       Date:  1994-08       Impact factor: 9.867

5.  Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor.

Authors:  M Gassmann; F Casagranda; D Orioli; H Simon; C Lai; R Klein; G Lemke
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

6.  Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family.

Authors:  G D Plowman; J M Culouscou; G S Whitney; J M Green; G W Carlton; L Foy; M G Neubauer; M Shoyab
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

7.  Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells.

Authors:  E Peles; S S Bacus; R A Koski; H S Lu; D Wen; S G Ogden; R B Levy; Y Yarden
Journal:  Cell       Date:  1992-04-03       Impact factor: 41.582

8.  Modulation of a Mr 175,000 c-neu receptor isoform in G8/DHFR cells by serum starvation.

Authors:  R J Epstein; B J Druker; T M Roberts; C D Stiles
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

9.  ARIA is concentrated in the synaptic basal lamina of the developing chick neuromuscular junction.

Authors:  A D Goodearl; A G Yee; A W Sandrock; G Corfas; G D Fischbach
Journal:  J Cell Biol       Date:  1995-09       Impact factor: 10.539

10.  ARIA can be released from extracellular matrix through cleavage of a heparin-binding domain.

Authors:  J A Loeb; G D Fischbach
Journal:  J Cell Biol       Date:  1995-07       Impact factor: 10.539
View more
  29 in total

1.  The Ras/Raf/ERK signalling pathway drives Schwann cell dedifferentiation.

Authors:  Marie C Harrisingh; Elena Perez-Nadales; David B Parkinson; Denise S Malcolm; Anne W Mudge; Alison C Lloyd
Journal:  EMBO J       Date:  2004-07-08       Impact factor: 11.598

2.  Microanatomy of axon/glial signaling during Wallerian degeneration.

Authors:  Amy D Guertin; Dan P Zhang; Kimberley S Mak; John A Alberta; Haesun A Kim
Journal:  J Neurosci       Date:  2005-03-30       Impact factor: 6.167

3.  Berberine promotes axonal regeneration in injured nerves of the peripheral nervous system.

Authors:  Ah Mi Han; Hwon Heo; Yunhee Kim Kwon
Journal:  J Med Food       Date:  2012-02-08       Impact factor: 2.786

4.  Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.

Authors:  Joshua T Dilworth; Jonathan W Wojtkowiak; Patricia Mathieu; Michael A Tainsky; John J Reiners; Raymond R Mattingly; Chad N Hancock
Journal:  Cancer Biol Ther       Date:  2008-12-07       Impact factor: 4.742

5.  Axonally derived neuregulin-1 is required for remyelination and regeneration after nerve injury in adulthood.

Authors:  Florence R Fricker; Natalia Lago; Sharmili Balarajah; Christoforos Tsantoulas; Shamil Tanna; Ning Zhu; Samaher K Fageiry; Mark Jenkins; Alistair N Garratt; Carmen Birchmeier; David L H Bennett
Journal:  J Neurosci       Date:  2011-03-02       Impact factor: 6.167

6.  AlphaB-crystallin regulates remyelination after peripheral nerve injury.

Authors:  Erin-Mai F Lim; Stan T Nakanishi; Vahid Hoghooghi; Shane E A Eaton; Alexandra L Palmer; Ariana Frederick; Jo A Stratton; Morgan G Stykel; Patrick J Whelan; Douglas W Zochodne; Jeffrey Biernaskie; Shalina S Ousman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

7.  The Agrin/MuSK signaling pathway is spatially segregated from the neuregulin/ErbB receptor signaling pathway at the neuromuscular junction.

Authors:  J C Trinidad; G D Fischbach; J B Cohen
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

8.  Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer.

Authors:  Chia C Portera; Janice M Walshe; Douglas R Rosing; Neelima Denduluri; Arlene W Berman; Ujala Vatas; Margarita Velarde; Catherine K Chow; Seth M Steinberg; Diana Nguyen; Sherry X Yang; Sandra M Swain
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

9.  Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response.

Authors:  Ramaswamy Bhuvaneswari; Yik Yuen Gan; Khee Chee Soo; Malini Olivo
Journal:  Mol Cancer       Date:  2009-11-02       Impact factor: 27.401

10.  Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer.

Authors:  B L Allen-Petersen; C J Carter; A M Ohm; M E Reyland
Journal:  Oncogene       Date:  2013-03-11       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.